The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer

Experimental Cell Research

Volumn 314, Issue 8, 2008, Pages 1881-1891

  Ko, Jen Chung ^a   Hong, Jhao Hao ^b   Wang, Lyu Han ^b   Lin, Yun Wei ^b  

^a Hsin Chu General Hospital   (Taiwan)

^b NATIONAL CHIAYI UNIVERSITY   (Taiwan)

Author keywords

Benzo a pyrene; Cytotoxicity; ERK1 2; Gefitinib; Mutagenicity; Rad51

Indexed keywords

26S PROTEASOME; ACTIN; BENZO[A]PYRENE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; POLYCYCLIC HYDROCARBON; PROTEASOME; RAD51 PROTEIN;

ARTICLE; CANCER RESISTANCE; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC TRANSFECTION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; LUNG CANCER; MUTAGENICITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; RADIOSENSITIVITY;

EID: 42649105426     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2008.02.013     Document Type: Article

References (67)

1. G.A. Silvestri M.P. Rivera Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists Chest 128 2005 3975 3984
2. S.H. Landis T. Murray S. Bolden P.A. Wingo Cancer statistics, 1999 CA Cancer J. Clin. 49 1999 8 31
3. D.G. Pfister D.H. Johnson C.G. Azzoli W. Sause T.J. Smith S. Baker Jr. J. Olak D. Stover J.R. Strawn A.T. Turrisi M.R. Somerfield American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J. Clin. Oncol. 22 2004 330 353
4. J.H. Schiller D. Harrington C.P. Belani C. Langer A. Sandler J. Krook J. Zhu D.H. Johnson Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N. Engl. J. Med. 346 2002 92 98
5. D.S. Salomon R. Brandt F. Ciardiello N. Normanno Epidermal growth factor-related peptides and their receptors in human malignancies Crit. Rev. Oncol./Hematol. 19 1995 183 232
6. D. Veale N. Kerr G.J. Gibson P.J. Kelly A.L. Harris The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival Br. J. Cancer 68 1993 162 165
7. C. Arteaga Targeting HER1/EGFR: a molecular approach to cancer therapy Semin. Oncol. 30 2003 3 14
8. E. Raymond S. Faivre J.P. Armand Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy Drugs 60 Suppl 1 2000 15 23 discussion 41–12
9. J. Mendelsohn The epidermal growth factor receptor as a target for cancer therapy Endocr. Relat. Cancer 8 2001 3 9
10. M. Ono A. Hirata T. Kometani M. Miyagawa S. Ueda H. Kinoshita T. Fujii M. Kuwano Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation Mol. Cancer Ther. 3 2004 465 472
11. T.J. Lynch D.W. Bell R. Sordella S. Gurubhagavatula R.A. Okimoto B.W. Brannigan P.L. Harris S.M. Haserlat J.G. Supko F.G. Haluska D.N. Louis D.C. Christiani J. Settleman D.A. Haber Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139
12. J.G. Paez P.A. Janne J.C. Lee S. Tracy H. Greulich S. Gabriel P. Herman F.J. Kaye N. Lindeman T.J. Boggon K. Naoki H. Sasaki Y. Fujii M.J. Eck W.R. Sellers B.E. Johnson M. Meyerson EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
13. R. Rosell M. Taron N. Reguart D. Isla T. Moran Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway Clin. Cancer Res. 12 2006 7222 7231
14. K. Erjala M. Sundvall T.T. Junttila N. Zhang M. Savisalo P. Mali J. Kulmala J. Pulkkinen R. Grenman K. Elenius Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells Clin. Cancer Res. 12 2006 4103 4111
15. A. Shinohara H. Ogawa T. Ogawa Rad51 protein involved in repair and recombination in S. cerevisiae is a RecA-like protein Cell 69 1992 457 470
16. T. Haaf E.I. Golub G. Reddy C.M. Radding D.C. Ward Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes Proc. Natl. Acad. Sci. U. S. A. 92 1995 2298 2302
17. P. Baumann F.E. Benson S.C. West Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro Cell 87 1996 757 766
18. P. Baumann S.C. West Role of the human RAD51 protein in homologous recombination and double-stranded-break repair Trends Biochem. Sci. 23 1998 247 251
19. M. Tarsounas D. Davies S.C. West BRCA2-dependent and independent formation of RAD51 nuclear foci Oncogene 22 2003 1115 1123
20. H. Maacke S. Opitz K. Jost W. Hamdorf W. Henning S. Kruger A.C. Feller A. Lopens K. Diedrich E. Schwinger H.W. Sturzbecher Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer Int. J. Cancer 88 2000 907 913
21. K. Yoshikawa T. Ogawa R. Baer H. Hemmi K. Honda A. Yamauchi T. Inamoto K. Ko S. Yazumi H. Motoda H. Kodama S. Noguchi A.F. Gazdar Y. Yamaoka R. Takahashi Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas Int. J. Cancer 88 2000 28 36
22. S. Vispe C. Cazaux C. Lesca M. Defais Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation Nucleic Acids Res. 26 1998 2859 2864
23. G. Christodoulopoulos A. Malapetsa H. Schipper E. Golub C. Radding L.C. Panasci Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia Clin. Cancer Res. 5 1999 2178 2184
24. H. Maacke K. Jost S. Opitz S. Miska Y. Yuan L. Hasselbach J. Luttges H. Kalthoff H.W. Sturzbecher DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma Oncogene 19 2000 2791 2795
25. V.E. Bello R.S. Aloyz G. Christodoulopoulos L.C. Panasci Homologous recombinational repair vis-a-vis chlorambucil resistance in chronic lymphocytic leukemia Biochem. Pharmacol. 63 2002 1585 1588
26. P.P. Connell K. Jayathilaka D.J. Haraf R.R. Weichselbaum E.E. Vokes M.W. Lingen Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers Int. J. Oncol. 28 2006 1113 1119
27. S. Schneider D.J. Park D. Yang A. El-Khoueiry A. Sherrod S. Groshen O. Streeter S. Iqbal K.D. Danenberg H.J. Lenz Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation Pharmacogenet. Genomics 16 2006 555 563
28. G.B. Qiao Y.L. Wu X.N. Yang W.Z. Zhong D. Xie X.Y. Guan D. Fischer H.C. Kolberg S. Kruger H.W. Stuerzbecher High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients Br. J. Cancer 93 2005 137 143
29. T. Takenaka I. Yoshino H. Kouso T. Ohba T. Yohena A. Osoegawa F. Shoji Y. Maehara Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer Int. J. Cancer 121 2007 895 900
30. T.P. Garrington G.L. Johnson Organization and regulation of mitogen-activated protein kinase signaling pathways Curr. Opin. Cell Biol. 11 1999 211 218
31. W. Kolch Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions Biochem. J. 351 Pt 2 2000 289 305
32. A.R. Nebreda A. Porras p38 MAP kinases: beyond the stress response Trends Biochem. Sci. 25 2000 257 260
33. L. Chang M. Karin Mammalian MAP kinase signalling cascades Nature 410 2001 37 40
34. W. Kolch Coordinating ERK/MAPK signalling through scaffolds and inhibitors Nat. Rev., Mol. Cell Biol. 6 2005 827 837
35. C.J. Marshall Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation Cell 80 1995 179 185
36. H.V. Gelboin Benzo[alpha]pyrene metabolism, activation and carcinogenesis: role and regulation of mixed-function oxidases and related enzymes Physiol. Rev. 60 1980 1107 1166
37. E. Braithwaite X. Wu Z. Wang Repair of DNA lesions induced by polycyclic aromatic hydrocarbons in human cell-free extracts: involvement of two excision repair mechanisms in vitro Carcinogenesis 19 1998 1239 1246
38. M. Krawczak D.N. Cooper p53 mutations, benzo[a]pyrene and lung cancer Mutagenesis 13 1998 319 320
39. D.H. Phillips Fifty years of benzo(a)pyrene Nature 303 1983 468 472
40. A. Dipple K. Peltonen S.C. Cheng H. Ross C.A. Bigger Chemical and mutagenic specificities of polycyclic aromatic hydrocarbon carcinogens Adv. Exp. Med. Biol. 354 1994 101 112
41. A. Dipple DNA adducts of chemical carcinogens Carcinogenesis 16 1995 437 441
42. G.S. Akerman B.A. Rosenzweig O.E. Domon L.J. McGarrity L.R. Blankenship C.A. Tsai S.J. Culp J.T. MacGregor F.D. Sistare J.J. Chen S.M. Morris Gene expression profiles and genetic damage in benzo(a)pyrene diol epoxide-exposed TK6 cells Mutat. Res. 549 2004 43 64
43. O. Nwagbara S.F. Darling-Reed A. Tucker C. Harris M. Abazinge R.D. Thomas R.D. Gragg Induction of cell death, DNA strand breaks, and cell cycle arrest in DU145 human prostate carcinoma cell line by benzo[a]pyrene and benzo[a]pyrene-7,8-diol-9,10-epoxide Int. J. Environ. Res. Public Health 4 2007 10 14
44. A.D. Burdick I.D. Ivnitski-Steele F.T. Lauer S.W. Burchiel PYK2 mediates anti-apoptotic AKT signaling in response to benzo[a]pyrene diol epoxide in mammary epithelial cells Carcinogenesis 27 2006 2331 2340
45. J.J. Mukherjee H.C. Sikka Attenuation of BPDE-induced p53 accumulation by TPA is associated with a decrease in stability and phosphorylation of p53 and downregulation of NFkappaB activation: role of p38 MAP kinase Carcinogenesis 27 2006 631 638
46. S. Song S.M. Lippman Y. Zou X. Ye J.A. Ajani X.C. Xu Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression Oncogene 24 2005 8268 8276
47. A. Solhaug S. Ovrebo S. Mollerup M. Lag P.E. Schwarze S. Nesnow J.A. Holme Role of cell signaling in B[a]P-induced apoptosis: characterization of unspecific effects of cell signaling inhibitors and apoptotic effects of B[a]P metabolites Chem. Biol. Interact. 151 2005 101 119
48. S.L. Tannheimer S.P. Ethier K.K. Caldwell S.W. Burchiel Benzo[a]pyrene- and TCDD-induced alterations in tyrosine phosphorylation and insulin-like growth factor signaling pathways in the MCF-10A human mammary epithelial cell line Carcinogenesis 19 1998 1291 1297
49. H. Jyonouchi S. Sun K. Iijima M. Wang S.S. Hecht Effects of anti-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene on human small airway epithelial cells and the protective effects of myo-inositol Carcinogenesis 20 1999 139 145
50. Y.W. Lin S.M. Chuang J.L. Yang ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway J. Biol. Chem. 278 2003 21534 21541
51. Y.W. Lin S.M. Chuang J.L. Yang Persistent activation of ERK1/2 by lead acetate increases nucleotide excision repair synthesis and confers anti-cytotoxicity and anti-mutagenicity Carcinogenesis 24 2003 53 61
52. B.T. Bennett K.L. Knight Cellular localization of human Rad51C and regulation of ubiquitin-mediated proteolysis of Rad51 J. Cell. Biochem. 96 2005 1095 1109
53. F. Ciardiello R. Caputo R. Bianco V. Damiano G. Pomatico S. De Placido A.R. Bianco G. Tortora Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor Clin. Cancer Res. 6 2000 2053 2063
54. J. Baselga S.D. Averbuch ZD1839 (‘Iressa’) as an anticancer agent Drugs 60 Suppl 1 2000 33 40 discussion 41–32
55. F.M. Sirotnak M.F. Zakowski V.A. Miller H.I. Scher M.G. Kris Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase Clin. Cancer Res. 6 2000 4885 4892
56. A.P. Gilmore A.J. Valentijn P. Wang A.M. Ranger N. Bundred M.J. O'Hare A. Wakeling S.J. Korsmeyer C.H. Streuli Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor J. Biol. Chem. 277 2002 27643 27650
57. B. Friedmann M. Caplin J.A. Hartley D. Hochhauser Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839) Clin. Cancer Res. 10 2004 6476 6486
58. B.J. Friedmann M. Caplin B. Savic T. Shah C.J. Lord A. Ashworth J.A. Hartley D. Hochhauser Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment Mol. Cancer Ther. 5 2006 209 218
59. M.G. Kris R.B. Natale R.S. Herbst T.J. Lynch Jr. D. Prager C.P. Belani J.H. Schiller K. Kelly H. Spiridonidis A. Sandler K.S. Albain D. Cella M.K. Wolf S.D. Averbuch J.J. Ochs A.C. Kay Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2003 2149 2158
60. T. Tsuzuki Y. Fujii K. Sakumi Y. Tominaga K. Nakao M. Sekiguchi A. Matsushiro Y. Yoshimura T. Morita Targeted disruption of the Rad51 gene leads to lethality in embryonic mice Proc. Natl. Acad. Sci. U. S. A. 93 1996 6236 6240
61. E. Sonoda M.S. Sasaki J.M. Buerstedde O. Bezzubova A. Shinohara H. Ogawa M. Takata Y. Yamaguchi-Iwai S. Takeda Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death EMBO J. 17 1998 598 608
62. C. Lundin N. Schultz C. Arnaudeau A. Mohindra L.T. Hansen T. Helleday RAD51 is involved in repair of damage associated with DNA replication in mammalian cells J. Mol. Biol. 328 2003 521 535
63. A. Slupianek G. Hoser I. Majsterek A. Bronisz M. Malecki J. Blasiak R. Fishel T. Skorski Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis Mol. Cell. Biol. 22 2002 4189 4201
64. E. Raderschall K. Stout S. Freier V. Suckow S. Schweiger T. Haaf Elevated levels of Rad51 recombination protein in tumor cells Cancer Res. 62 2002 219 225
65. S.J. Xia M.A. Shammas R.J. Shmookler Reis Elevated recombination in immortal human cells is mediated by HsRAD51 recombinase Mol. Cell. Biol. 17 1997 7151 7158
66. J.S. Russell K. Brady W.E. Burgan M.A. Cerra K.A. Oswald K. Camphausen P.J. Tofilon Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity Cancer Res. 63 2003 7377 7383
67. P. Chinnaiyan S. Huang G. Vallabhaneni E. Armstrong S. Varambally S.A. Tomlins A.M. Chinnaiyan P.M. Harari Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva) Cancer Res. 65 2005 3328 3335